The observation [7] that VCD exerted hypoglycemia-specific toxicity in colon carcinoma cells, possibly via the inhibition of GRP78, prompted us to hypothesize that this compound potentially might exert therapeutic benefit in TNBC. The gene discussed is HSPA5; the disease is Hypoglycemia.